<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>HEALTH + VISION</title>
	<atom:link href="http://healthstrategy.wordpress.com/feed/" rel="self" type="application/rss+xml" />
	<link>http://healthstrategy.wordpress.com</link>
	<description></description>
	<lastBuildDate>Fri, 26 Jun 2009 19:10:47 +0000</lastBuildDate>
	<generator>http://wordpress.com/</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<cloud domain='healthstrategy.wordpress.com' port='80' path='/?rsscloud=notify' registerProcedure='' protocol='http-post' />
<image>
		<url>http://www.gravatar.com/blavatar/bf4fe7d51b035551504a32c559effbbd?s=96&#038;d=http://s.wordpress.com/i/buttonw-com.png</url>
		<title>HEALTH + VISION</title>
		<link>http://healthstrategy.wordpress.com</link>
	</image>
			<item>
		<title>Patent exclusivity and biosimilars: what&#8217;s a reasonable compromise?</title>
		<link>http://healthstrategy.wordpress.com/2009/06/26/patent-exclusivity-and-biosimilars-whats-a-reasonable-compromise/</link>
		<comments>http://healthstrategy.wordpress.com/2009/06/26/patent-exclusivity-and-biosimilars-whats-a-reasonable-compromise/#comments</comments>
		<pubDate>Fri, 26 Jun 2009 19:08:09 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drug approvals and regulation]]></category>
		<category><![CDATA[Health and drug costs]]></category>
		<category><![CDATA[health economics]]></category>
		<category><![CDATA[BIO]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[exclusivity]]></category>
		<category><![CDATA[Waxman]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=143</guid>
		<description><![CDATA[The biotech industry, through the Biotechnology Industry Organization (BIO), has been arguing in favor of a 12-year exclusivity period for new biological agents from the initial date of approval.
Senator Waxman (he of the Waxman-Hatch amendment to the Food Drug and Cosmetic Act back in 1984) has been pushing a bill that would limit exclusivity for [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=143&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2009/06/26/patent-exclusivity-and-biosimilars-whats-a-reasonable-compromise/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Hyperbole, hysteria, and health care reform</title>
		<link>http://healthstrategy.wordpress.com/2009/06/25/hyperbole-hysteria-and-health-care-reform/</link>
		<comments>http://healthstrategy.wordpress.com/2009/06/25/hyperbole-hysteria-and-health-care-reform/#comments</comments>
		<pubDate>Thu, 25 Jun 2009 16:22:28 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[health economics]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=141</guid>
		<description><![CDATA[The idea that we might all try to cooperate and collaborate in the interests of developing a new and better health care system that serves the needs of all Americans appears to be vanishing rapidly out of the windows of buildings in Washington. Perhaps the best we can now hope is that the pragmatism for [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=141&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2009/06/25/hyperbole-hysteria-and-health-care-reform/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>A sad case all around &#8230;</title>
		<link>http://healthstrategy.wordpress.com/2008/10/17/a-sad-case-all-around/</link>
		<comments>http://healthstrategy.wordpress.com/2008/10/17/a-sad-case-all-around/#comments</comments>
		<pubDate>Fri, 17 Oct 2008 14:15:56 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Business strategy]]></category>
		<category><![CDATA[Drug approvals and regulation]]></category>
		<category><![CDATA[Health and drug costs]]></category>
		<category><![CDATA[Baron]]></category>
		<category><![CDATA[ethics]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[myeloma]]></category>
		<category><![CDATA[Tysabri]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=125</guid>
		<description><![CDATA[I need to state a theoretical conflict of interests up front. I am a member of the Board of Directors of the International Myeloma Foundation. So, having said that &#8230;
Fred Baron, a well known Texas-based lawyer and the former finance chairman of John Edwards&#8217;s presidential campaign, has progressive multiple myeloma. I am not aware of the [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=125&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2008/10/17/a-sad-case-all-around/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Grasping the health care cost nettle</title>
		<link>http://healthstrategy.wordpress.com/2008/10/10/grasping-the-health-care-cost-nettle/</link>
		<comments>http://healthstrategy.wordpress.com/2008/10/10/grasping-the-health-care-cost-nettle/#comments</comments>
		<pubDate>Fri, 10 Oct 2008 12:29:55 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Business strategy]]></category>
		<category><![CDATA[Health and drug costs]]></category>
		<category><![CDATA[health economics]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=114</guid>
		<description><![CDATA[So between Bernadine Healy&#8217;s recent article in U.S. News and World Report (&#8220;Is healthcare Armageddon next?&#8221;) and Bob Ehrlich&#8217;s response to that article (&#8220;The health bubble&#8220;) in DTC Perspectives, could it be possible that we are finally deciding to grasp the viscious health care cost nettle that is set to sting us all if we [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=114&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2008/10/10/grasping-the-health-care-cost-nettle/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Is UK&#8217;s NHS offering a &#8220;new model&#8221; for pharmaceutical pricing?</title>
		<link>http://healthstrategy.wordpress.com/2008/10/07/is-uks-nhs-offering-a-new-model-for-pharmaceutical-pricing/</link>
		<comments>http://healthstrategy.wordpress.com/2008/10/07/is-uks-nhs-offering-a-new-model-for-pharmaceutical-pricing/#comments</comments>
		<pubDate>Tue, 07 Oct 2008 17:22:50 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Business strategy]]></category>
		<category><![CDATA[Health and drug costs]]></category>
		<category><![CDATA[health economics]]></category>
		<category><![CDATA[pharmaceuticals]]></category>
		<category><![CDATA[pricing]]></category>
		<category><![CDATA[UK]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=105</guid>
		<description><![CDATA[A report from London in today&#8217;s Daily Telegraph suggests that:
The Government is urging pharmaceutical companies to lower their initial prices for new drugs, with the promise that the [National Health Service] will pay more for them if evidence proves greater effectiveness.
Could this be the beginning of a chink in the concrete wall that has been growing on the [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=105&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2008/10/07/is-uks-nhs-offering-a-new-model-for-pharmaceutical-pricing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>I&#8217;d have more to say but I can&#8217;t stop laughing</title>
		<link>http://healthstrategy.wordpress.com/2008/10/07/id-have-more-to-say-but-i-cant-stop-laughing/</link>
		<comments>http://healthstrategy.wordpress.com/2008/10/07/id-have-more-to-say-but-i-cant-stop-laughing/#comments</comments>
		<pubDate>Tue, 07 Oct 2008 12:39:52 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Business strategy]]></category>
		<category><![CDATA[Drug approvals and regulation]]></category>
		<category><![CDATA[FDA]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=98</guid>
		<description><![CDATA[So you&#8217;ll be glad to know it&#8217;s not just the health care and the pharmaceutical industries that have some fundamental problems with their communication issues and how these lead to a lousy public image &#8230;. 
Now we can add the FDA to the list of the apparently utterly naive!
I don&#8217;t need to comment further, just read either [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=98&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2008/10/07/id-have-more-to-say-but-i-cant-stop-laughing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Relative reputation: a comparative view of the healthcare industry</title>
		<link>http://healthstrategy.wordpress.com/2008/08/14/relative-reputation-a-comparative-view-of-the-healthcare-industry/</link>
		<comments>http://healthstrategy.wordpress.com/2008/08/14/relative-reputation-a-comparative-view-of-the-healthcare-industry/#comments</comments>
		<pubDate>Thu, 14 Aug 2008 19:33:15 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Business strategy]]></category>
		<category><![CDATA[Health and drug costs]]></category>
		<category><![CDATA[reputation industry consumer Harris attitudes]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=83</guid>
		<description><![CDATA[Every year at about this time (since the late 1990s), Harris Interactive conducts a poll in which they ask consumers whether they think specific industries are doing a good job (or not). The results of the 2008 poll were just published.
These polls have always included data on four health care-related industries, as follows:

Hospitals
Health insurance companies
Managed [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=83&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2008/08/14/relative-reputation-a-comparative-view-of-the-healthcare-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>

		<media:content url="http://healthstrategy.files.wordpress.com/2008/08/harris.png?w=300" medium="image" />
	</item>
		<item>
		<title>Sharing in a glass half full</title>
		<link>http://healthstrategy.wordpress.com/2008/08/12/sharing-in-a-glass-half-full/</link>
		<comments>http://healthstrategy.wordpress.com/2008/08/12/sharing-in-a-glass-half-full/#comments</comments>
		<pubDate>Tue, 12 Aug 2008 17:40:11 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Business strategy]]></category>
		<category><![CDATA[Drug approvals and regulation]]></category>
		<category><![CDATA[Drug development / clinical trials]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[future]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[NME]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=75</guid>
		<description><![CDATA[An insightful article by Robert Goldberg of the Centers for Medicine in the Public Interest, entitled &#8220;The future of drug development,&#8221; appeared today on the FiercePharma web site.
One can only commend Dr. Goldberg for his &#8220;glass half full&#8221; view of the current situation at the FDA. The moaning about the FDA&#8217;s supposed failure to approve [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=75&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2008/08/12/sharing-in-a-glass-half-full/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>NICE &#8230; or not so nice? The economics of perception.</title>
		<link>http://healthstrategy.wordpress.com/2008/08/07/nice-or-not-nice-the-economics-of-perception/</link>
		<comments>http://healthstrategy.wordpress.com/2008/08/07/nice-or-not-nice-the-economics-of-perception/#comments</comments>
		<pubDate>Thu, 07 Aug 2008 14:16:48 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Business strategy]]></category>
		<category><![CDATA[Drug approvals and regulation]]></category>
		<category><![CDATA[Health and drug costs]]></category>
		<category><![CDATA[health economics]]></category>
		<category><![CDATA[Add new tag]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cost]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[kidney]]></category>
		<category><![CDATA[NICE]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=67</guid>
		<description><![CDATA[Yesterday the UK&#8217;s National Institute for Health and Clinical Excellence (NICE) concluded that £35,000 a year (about US$70,000) for new drugs that have been proven to have efficacy in the management of advanced renal cell carcinoma (kidney cancer) is more than the National Health Service (NHS) can afford. 
According to a report in The Times NICE has:
concluded [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=67&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2008/08/07/nice-or-not-nice-the-economics-of-perception/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>What&#8217;s really driving the Roche bid for Genentech?</title>
		<link>http://healthstrategy.wordpress.com/2008/07/22/whats-really-driving-the-roche-bid-for-genentech/</link>
		<comments>http://healthstrategy.wordpress.com/2008/07/22/whats-really-driving-the-roche-bid-for-genentech/#comments</comments>
		<pubDate>Tue, 22 Jul 2008 13:28:16 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=60</guid>
		<description><![CDATA[Roche&#8217;s current business arrangements with Genentech give Roche all non-US marketing and development rights to Genentech&#8217;s product line through 2015. While that may seem a long way off to some people, Genentech apparently has as many as 100 products in it&#8217;s current development pipeline, and as these products move into clinical trials, the ability to [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=60&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2008/07/22/whats-really-driving-the-roche-bid-for-genentech/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Will downturn in scripts drive home the message?</title>
		<link>http://healthstrategy.wordpress.com/2008/07/16/will-downturn-in-scripts-drive-home-the-message/</link>
		<comments>http://healthstrategy.wordpress.com/2008/07/16/will-downturn-in-scripts-drive-home-the-message/#comments</comments>
		<pubDate>Wed, 16 Jul 2008 12:40:46 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Business strategy]]></category>
		<category><![CDATA[Health and drug costs]]></category>
		<category><![CDATA[health economics]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=53</guid>
		<description><![CDATA[IMS Health data for the first quarter of 2008 in the US apparently suggest that:

the number of scripts dispensed is growing at its slowest rate in at least a decade
the rate of prescription growth has fallen steadily since early 2007
the number of scripts dispensed may actually have fallen in 2Q08


Furthermore, for May 2008, branded products represented [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=53&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2008/07/16/will-downturn-in-scripts-drive-home-the-message/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Talking to national payers</title>
		<link>http://healthstrategy.wordpress.com/2008/07/07/talking-to-national-payers/</link>
		<comments>http://healthstrategy.wordpress.com/2008/07/07/talking-to-national-payers/#comments</comments>
		<pubDate>Mon, 07 Jul 2008 13:44:36 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Business strategy]]></category>
		<category><![CDATA[Drug approvals and regulation]]></category>
		<category><![CDATA[Drug development / clinical trials]]></category>
		<category><![CDATA[Health and drug costs]]></category>
		<category><![CDATA[health economics]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=51</guid>
		<description><![CDATA[Now this looks like a bright idea! Let&#8217;s actually talk to the ultimate payers and give them some idea what we&#8217;re thinking of moving through the development pipeline so that the payers can tell us up front what they might be prepared to pay for. 
According the the Wall Street Journal this morning, GlaxoSmithKline and Novartis [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=51&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2008/07/07/talking-to-national-payers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Reputation, expectation, and social stature</title>
		<link>http://healthstrategy.wordpress.com/2008/06/30/reputation-expectation-and-social-stature/</link>
		<comments>http://healthstrategy.wordpress.com/2008/06/30/reputation-expectation-and-social-stature/#comments</comments>
		<pubDate>Mon, 30 Jun 2008 19:54:49 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=50</guid>
		<description><![CDATA[Well, the good news is that the pharmaceutical industry&#8217;s reputation appears to be better than President Bush&#8217;s. What&#8217;s the bad news? Its &#8220;job approval rating&#8221; is only slightly better than the President&#8217;s!

Last week Harris Interactive issued survey data showing that the pharmaceutical industry&#8217;s repuation declined 2 points in 2007. Only 26 percent of American consumers now give drug [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=50&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2008/06/30/reputation-expectation-and-social-stature/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Drugmakers &#8220;not believable?&#8221; Why would anyone be surprised?</title>
		<link>http://healthstrategy.wordpress.com/2008/05/29/drugmakers-not-believable-why-would-anyone-be-surprised/</link>
		<comments>http://healthstrategy.wordpress.com/2008/05/29/drugmakers-not-believable-why-would-anyone-be-surprised/#comments</comments>
		<pubDate>Thu, 29 May 2008 18:00:20 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Business strategy]]></category>
		<category><![CDATA[Health and drug costs]]></category>
		<category><![CDATA[health economics]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=49</guid>
		<description><![CDATA[When you have a clear conflict of interests, you have to work 20 times as hard if you want to be believable! But rather than seeking transparency and fostering trust, all too many pharmaceutical companies have continued to conduct &#8220;business as usual.&#8221;
A European Commission study has now found that healthcare professionals and payers are &#8220;mostly [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=49&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2008/05/29/drugmakers-not-believable-why-would-anyone-be-surprised/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>&#8220;Differential pricing&#8221; in emerging markets: Part II</title>
		<link>http://healthstrategy.wordpress.com/2008/05/22/differential-pricing-in-emerging-markets-part-ii/</link>
		<comments>http://healthstrategy.wordpress.com/2008/05/22/differential-pricing-in-emerging-markets-part-ii/#comments</comments>
		<pubDate>Thu, 22 May 2008 17:20:17 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Uncategorized]]></category>

		<guid isPermaLink="false">http://healthstrategy.wordpress.com/?p=48</guid>
		<description><![CDATA[Apparently someone in the major media has finally picked up on the strategic initiatives evolving at at least a couple of the major pharmaceutical companies to use differential pricing strategies and focused marketing teams to penetrate the emerging pharmaceutical markets from China, India, and Indonesia to Columbia, Panama, and Brazil. We first blogged about this [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=healthstrategy.wordpress.com&blog=3202646&post=48&subd=healthstrategy&ref=&feed=1" />]]></description>
		<wfw:commentRss>http://healthstrategy.wordpress.com/2008/05/22/differential-pricing-in-emerging-markets-part-ii/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="http://0.gravatar.com/avatar/682f740e1805396aa57cefaa6609284f?s=96&#38;d=http%3A%2F%2F0.gravatar.com%2Favatar%2Fad516503a11cd5ca435acc9bb6523536%3Fs%3D96" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
	</channel>
</rss>